Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations
Background The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib
is an effective treatment for recurrent or advanced lung cancer harboring EGFR gene …
is an effective treatment for recurrent or advanced lung cancer harboring EGFR gene …
The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor
R Ko, H Kenmotsu, Y Hisamatsu, H Akamatsu… - International journal of …, 2015 - Springer
Background It is unclear whether there is a difference in the effect of gefitinib treatment
between patients with postoperative recurrent non-small cell lung cancer (NSCLC) and …
between patients with postoperative recurrent non-small cell lung cancer (NSCLC) and …
Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study
BACKGROUND: Patients with lung adenocarcinoma who carry epidermal growth factor
receptor (EGFR) gene mutations respond remarkably well to EGFR tyrosine kinase inhibitor …
receptor (EGFR) gene mutations respond remarkably well to EGFR tyrosine kinase inhibitor …
Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation
K Takamochi, K Suzuki, H Sugimura, K Funai, H Mori… - Lung Cancer, 2007 - Elsevier
Gefitinib is the first approved epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) for the treatment of patients with advanced non-small cell lung cancer …
inhibitor (TKI) for the treatment of patients with advanced non-small cell lung cancer …
The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma
F Shoji, T Yano, I Yoshino, D Mori, F Yamasaki… - European Journal of …, 2008 - Elsevier
AIMS: Gefitinib shows prominent anti-tumor activity against advanced or recurrent non-small
cell lung cancer (NSCLC). However, most gefitinib-responsive patients ultimately relapse …
cell lung cancer (NSCLC). However, most gefitinib-responsive patients ultimately relapse …
Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer
J Okami, K Taniguchi, M Higashiyama, J Maeda, K Oda… - Oncology, 2008 - karger.com
Abstract Background and Objectives: The association between epidermal growth factor
receptor (EGFR) mutations and response to EGFR tyrosine kinase inhibitor (TKI) has been …
receptor (EGFR) mutations and response to EGFR tyrosine kinase inhibitor (TKI) has been …
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non–small-cell lung cancer with …
T Mitsudomi, T Kosaka, H Endoh, Y Horio… - Journal of Clinical …, 2005 - ascopubs.org
Purpose To evaluate the relationship between mutations of the epidermal growth factor
receptor (EGFR) gene and the effectiveness of gefitinib treatment in patients with recurrent …
receptor (EGFR) gene and the effectiveness of gefitinib treatment in patients with recurrent …
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations
K Asami, T Okuma, T Hirashima, M Kawahara, S Atagi… - Lung Cancer, 2013 - Elsevier
BACKGROUND: Gefitinib is an effective treatment for patients with non-small cell lung
cancer who harbor activating epidermal growth factor receptor (EGFR) mutations. However …
cancer who harbor activating epidermal growth factor receptor (EGFR) mutations. However …
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
K Sugio, H Uramoto, T Onitsuka, M Mizukami, Y Ichiki… - Lung Cancer, 2009 - Elsevier
BACKGROUND: This study prospectively assessed the efficacy of gefitinib and the survival
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …
Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature
I Marech, A Vacca, A Gnoni, N Silvestris… - Tumori …, 2013 - journals.sagepub.com
Gefitinib is the current first-line treatment for advanced lung adenocarcinoma with epidermal
growth factor receptor (EGFR) gene mutations. The possibility of using gefitinib as …
growth factor receptor (EGFR) gene mutations. The possibility of using gefitinib as …
相关搜索
- gefitinib treatment lung cancer
- growth factor gefitinib in patients
- egfr mutations continued treatment
- gefitinib treatment postoperative recurrence
- postoperative recurrence lung cancer
- lung adenocarcinoma effect of gefitinib
- patients with recurrence effect of gefitinib
- gefitinib treatment prolonged survival
- lung adenocarcinoma survival of patients
- egfr mutations progressive disease
- gefitinib treatment surgical resection
- prolonged survival lung cancer
- postoperative recurrence prognostic factors
- gefitinib treatment lung adenocarcinoma
- growth factor effect of gefitinib
- lung adenocarcinoma patients with recurrence